Our Network Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) Tags: #Rare disease #Pharmaceutical Industry #AstraZeneca #Regulation Approval exemplifies commitment to broadening access for patients living with rare diseases globally.
